Zacks: Artelo Biosciences (NASDAQ:ARTL) Given Consensus Recommendation of “Strong Buy” by Analysts
Artelo Biosciences (NASDAQ:ARTL) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.
Zacks has also given Artelo Biosciences an industry rank of 69 out of 256 based on the ratings given to related companies.
Separately, Maxim Group reaffirmed a “buy” rating and set a $22.50 target price (up previously from $4.50) on shares of LendingClub in a report on Tuesday, July 9th.
Artelo Biosciences Company Profile
Artelo Biosciences, Inc, an ethical biopharmaceutical company, focuses on developing, licensing, and commercializing cannabinoid therapeutic treatments. Its products pipeline includes ART12.11, a cannabidiol composition for the treatment of inflammatory bowel disease, stroke, and rare/orphan diseases; ART26.12, an endocannabinoid transport protein (FABP5) inhibitor for the treatment of breast cancer, prostate cancer, and neuropathic and nociceptive pain; and ART27.13 for the treatment of cancer and cachexia.
Featured Story: The basics of gap trading strategies
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Artelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.